Beam Therapeutics Inc BEAM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
-
Beam Therapeutics Announces Transition of Chief Financial Officer
-
Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront
-
Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026
Trading Information
- Previous Close Price
- $22.94
- Day Range
- $22.95–23.73
- 52-Week Range
- $16.95–49.50
- Bid/Ask
- $23.03 / $23.36
- Market Cap
- $1.93 Bil
- Volume/Avg
- 477,400 / 967,815
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 461
- Website
- https://www.beamtx.com
Comparables
Valuation
|
Metric
|
BEAM
|
VERV
|
PRME
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.21 | 0.73 | 2.08 |
Price/Sales | 5.27 | 17.16 | 588.54 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BEAM
|
VERV
|
PRME
|
|---|---|---|---|
Quick Ratio | 5.69 | 14.34 | 7.85 |
Current Ratio | 5.81 | 14.64 | 8.23 |
Interest Coverage | — | — | — |
Quick Ratio
BEAM
VERV
PRME
Profitability
|
Metric
|
BEAM
|
VERV
|
PRME
|
|---|---|---|---|
Return on Assets (Normalized) | −3.74% | −23.76% | −70.16% |
Return on Equity (Normalized) | −5.80% | −30.33% | −89.48% |
Return on Invested Capital (Normalized) | −8.71% | −30.18% | −78.46% |
Return on Assets
BEAM
VERV
PRME
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wflzptkdhx | Rcrr | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dzpqhfrx | Xnfrbn | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tnhmsqkt | Dhcjybp | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zdtzykpl | Qyzvf | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Bdxnkhqjn | Phpr | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bpkpmffpq | Jxpc | $28.5 Bil | |||
| Moderna Inc
MRNA
| Lhnqrktbd | Lxzx | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Fzpfdzm | Lvpk | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Drzklsl | Cghybc | $13.0 Bil | |||
| Incyte Corp
INCY
| Xgtqwqv | Lpcwkyr | $12.9 Bil |
United States